Godavari Biorefineries Secures Japanese Patent for Cancer Treatment Compounds; Shares Up Over 6%

Mumbai, June 16: Godavari Biorefineries announced that the Japan Patent Office has granted a patent titled “5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer”, according to an exchange filing made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company said the patent covers a novel class of compounds that demonstrated strong inhibitory effects on cancer cells and cancer stem cells.

According to the disclosure, the patented compounds have shown significant efficacy against multiple cancer types, including breast cancer and prostate cancer.

The grant adds another intellectual property asset to the company’s research portfolio and expands protection for its oncology-focused innovations in one of the world’s major pharmaceutical markets.

The company attached the grant certificate with the filing and stated that the disclosure was being made for investor information and record purposes.

Stock Market Snapshot

Godavari Biorefineries share price surged after investors reacted to the patent approval from Japan.

The stock traded at ₹301.65, up 6.07%, as of 10:39 IST on June 16, 2026.

Godavari Biorefineries share price witnessed strong buying momentum during morning trade as the market assessed the significance of the overseas intellectual property protection.

Patent grants are often viewed as strategic milestones for research-driven companies because they strengthen exclusivity, enhance commercial opportunities and support future licensing or product development initiatives.

Patent Strengthens Oncology Research Portfolio

The newly granted patent relates to compounds designed for cancer treatment and specifically targets cancer stem cells, which are increasingly being studied for their role in tumour recurrence and treatment resistance.

While the filing does not provide timelines for commercialisation or regulatory development, the patent provides legal protection for the underlying innovation in Japan.

For biotechnology and specialty research companies, patent protection across major international jurisdictions is often considered an important component of long-term value creation.

The development also reflects ongoing efforts by Indian companies to build global intellectual property portfolios in high-value healthcare and life sciences segments.

Company Background

Godavari Biorefineries Limited operates in bio-based chemicals, specialty products and research-driven industrial solutions.

The company manufactures a range of renewable chemicals, bio-based ingredients and value-added products serving sectors including pharmaceuticals, food, personal care and industrial applications.

In addition to its core manufacturing operations, the company has been investing in research and development initiatives aimed at expanding its intellectual property portfolio.

Conclusion

The Japanese patent grant marks a notable milestone for Godavari Biorefineries’ research programme and strengthens protection for its oncology-related innovation in an important international market.

Investors responded positively to the development, driving the stock more than 6% higher as the market evaluated the long-term strategic potential of the company’s growing patent portfolio.

Source:

• https://www.nseindia.com/get-quote/equity/GODAVARIB/Godavari-Biorefineries-Limited
• https://nsearchives.nseindia.com/corporate/GODAVARIBIO_16062026100805_Intimation_to_SE.pdf